AR086444A1 - Composiciones farmaceuticas y metodos para tratar el cancer - Google Patents

Composiciones farmaceuticas y metodos para tratar el cancer

Info

Publication number
AR086444A1
AR086444A1 ARP120101759A ARP120101759A AR086444A1 AR 086444 A1 AR086444 A1 AR 086444A1 AR P120101759 A ARP120101759 A AR P120101759A AR P120101759 A ARP120101759 A AR P120101759A AR 086444 A1 AR086444 A1 AR 086444A1
Authority
AR
Argentina
Prior art keywords
methods
pharmaceutical compositions
treat cancer
hydroxylase
lyase
Prior art date
Application number
ARP120101759A
Other languages
English (en)
Spanish (es)
Inventor
Iain James Webb
Oliver Rosen
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR086444A1 publication Critical patent/AR086444A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP120101759A 2011-05-17 2012-05-18 Composiciones farmaceuticas y metodos para tratar el cancer AR086444A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161486851P 2011-05-17 2011-05-17
US201161538246P 2011-09-23 2011-09-23

Publications (1)

Publication Number Publication Date
AR086444A1 true AR086444A1 (es) 2013-12-11

Family

ID=47177338

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101759A AR086444A1 (es) 2011-05-17 2012-05-18 Composiciones farmaceuticas y metodos para tratar el cancer

Country Status (7)

Country Link
EP (1) EP2709614A4 (fr)
JP (1) JP2014513730A (fr)
AR (1) AR086444A1 (fr)
CA (1) CA2836277A1 (fr)
TW (1) TW201309291A (fr)
UY (1) UY34078A (fr)
WO (1) WO2012158884A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS57309B1 (sr) 2010-02-16 2018-08-31 Aragon Pharmaceuticals Inc Modulatori androgenih receptora i njihove upotrebe
BR112013002655A2 (pt) 2010-08-04 2016-05-31 Pellficure Pharmaceuticals Inc novo tratamento de carcinoma de próstata
AR083916A1 (es) * 2010-11-18 2013-04-10 Takeda Pharmaceutical Metodo para tratar el cancer de mama y cancer de ovarios
MX371020B (es) * 2012-09-26 2020-01-13 Aragon Pharmaceuticals Inc Antiandrógenos para el tratamiento del cáncer de próstata resistente a la castración no metastásico.
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
WO2014158875A1 (fr) * 2013-03-14 2014-10-02 Pellficure Pharmaceuticals Inc. Nouvelle thérapie pour le carcinome de la prostate
EP3280448B1 (fr) 2015-04-10 2020-12-30 Capsugel Belgium NV Formulations lipidiques d'acétate d'abiratérone
GB201510684D0 (en) * 2015-06-17 2015-08-05 Almac Diagnostics Ltd Gene signatures predictive of metastatic disease
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264427A (en) * 1992-01-29 1993-11-23 Research Corporation Technologies, Inc. 20-substituted pregnene derivatives and their use as androgen synthesis inhibitors
NZ596260A (en) * 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
US20090124587A1 (en) * 2007-07-12 2009-05-14 Auerbach Alan H METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
AR069079A1 (es) * 2007-10-29 2009-12-30 Takeda Pharmaceutical Farmaco para la prevencion o el tratamiento de cancer

Also Published As

Publication number Publication date
EP2709614A4 (fr) 2015-04-15
TW201309291A (zh) 2013-03-01
UY34078A (es) 2012-11-30
WO2012158884A1 (fr) 2012-11-22
CA2836277A1 (fr) 2012-11-22
JP2014513730A (ja) 2014-06-05
EP2709614A1 (fr) 2014-03-26

Similar Documents

Publication Publication Date Title
AR086444A1 (es) Composiciones farmaceuticas y metodos para tratar el cancer
MX2021008610A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
ECSP13012764A (es) COMPUESTO DE IMIDAZO[4,5-C]QUINOLIN-2-ONA Y SU USO COMO INHIBIDOR DUAL DE CINASA PI3/mTOR
AR085668A1 (es) Terapias combinadas para malignidades hematologicas
CU20150163A7 (es) DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET
EA201690223A1 (ru) Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение
ECSP19025350A (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
TW200942536A (en) PIM kinase inhibitors and methods of their use
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
BR112012023021A2 (pt) compostos de indazol e seus usos
EP2513343A4 (fr) Procédés et compositions pour traiter l'inflammation de la peau
MX349159B (es) Derivados deuterados de ivacaftor.
AR084469A1 (es) Combinaciones de inhibidores de quinasas para el tratamiento del cancer
ECSP13012618A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogénesis
MX2014015004A (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
AR087107A1 (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
CR20110339A (es) Compuestos útiles para inhibir chk1
PE20160194A1 (es) Composiciones y metodos para tratar anemia
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
AR083916A1 (es) Metodo para tratar el cancer de mama y cancer de ovarios
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
ECSP088842A (es) Metodo para inhibir la cinasa del c?kit
BR112014004435A2 (pt) inibidores de quinase rock

Legal Events

Date Code Title Description
FB Suspension of granting procedure